



3FW  
Box 500

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of.:	§	
	§	
Oron YACOBY-ZEEVI et al	§	
	§	
Serial No.: 10/645,659	§	
	§	
Filed: August 22, 2003	§	Group Art Unit: 1644
	§	
For: HEPARANASE ACTIVITY	§	
NEUTRALIZING ANTI-	§	
HEPARANASE MONOCLONAL	§	
ANTIBODY AND OTHER ANTI-	§	
HEPARANASE ANTIBODIES	§	
	§	Attorney Docket: 26128
	§	
Examiner: Marianne Dibrino, Ph.D.	§	

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**ELECTION AND PRELIMINARY AMENDMENT**

Ms.:

This is in response to the United States Patent and Trademark Office Action mailed February 26, 2007, which response is being made on or before March 26, 2007, and for which no extension of time fee is due.

**Reference to the Sequence Listing begins on page 2**

**Amendments to the Claims begin on page 3.**

**Remarks begin on page 29.**

**In the Sequence Listing**

This is a response to the attached Office Communication dated February 26, 2007, which response is being made on or before March 26, 2007, and for which no extension fee is due.

By said Action, the Applicant is submitting a substitute paper copy of the "Sequence Listing", as well as a substitute computer readable form (CRF) copy of the "Sequence Listing". The content of the sequence listing information recorded in Computer Readable Form (CRF) is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**Statement**

The content of the sequence listing information recorded in computer readable form is identical to the written (on paper) sequence listing and includes no new matter.